Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Editor's pick
Gilead press release
25 April 2016
Access to healthcare

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

Editor's pick
ViiV Healthcare press release
25 April 2016
New & experimental HIV treatments

U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy

Editor's pick
Gilead press release
5 April 2016
PrEP

San Francisco HIV providers: What did you learn at CROI 2016?

Editor's pick
BETA blog
3 March 2016
New & experimental HIV treatments

ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa

Editor's pick
Abivax press release
2 March 2016
New & experimental HIV treatments

Gilead Sciences Announces FDA Approval of Odefsey as HIV-1 Treatment in Certain Patients

Editor's pick
Gilead press release
2 March 2016
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV

Editor's pick
Gilead press release
26 February 2016
The search for a cure

Sangamo BioSciences Presents Phase 2 Immunological Data from SB-728-T ZFP Therapeutic® HIV Program at CROI 2016

Editor's pick
Sangamo Biosciences press release
26 February 2016
PrEP

What is a drug “tail,” and what does it have to do with long-acting PrEP?

Editor's pick
BETA blog
25 February 2016
New & experimental HIV treatments

Gilead announces results from first study to evaluate switching to FTAF-based regimens from Truvada® (FTDF)-based regimens

Editor's pick
Gilead press release
24 February 2016
New & experimental HIV treatments

Once-daily Isentress non-inferior to twice-daily dose

Editor's pick
Merck press release
22 February 2016
The search for a cure

Adenosine deaminase may help the immune system fight HIV on its own

Editor's pick
Eurekalert Medicine & Health
3 February 2016
New & experimental HIV treatments

CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy

Editor's pick
Cytodyn Inc.
27 January 2016
New & experimental HIV treatments

Experimental Combination Surprises with Anti-HIV Effectiveness

Editor's pick
National Institute of Mental Health
27 January 2016
New & experimental HIV treatments

IV and Injectable HIV Treatments Are Much Discussed -- But Won't Be Here Anytime Soon

Editor's pick
TheBody Pro
21 January 2016
New & experimental HIV treatments

ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

Editor's pick
Medical News Today
13 January 2016
New & experimental HIV treatments

Janssen, ViiV Healthcare Formalize Injectable Rilpivirine + Cabotegravir Phase 3 as HIV Treatment

Editor's pick
Street Insider
8 January 2016
New & experimental HIV treatments

HIV Antibody Infusion Safely Suppresses Virus in Infected People

Editor's pick
National Institute of Allergy and Infectious Diseases (NIAID)
24 December 2015
New & experimental HIV treatments

Scientists reveal new phase of HIV infection

Editor's pick
Science Daily
19 December 2015
Pharmaceutical industry

Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare

Editor's pick
Bristol-Myers Squibb press release
18 December 2015
The search for a cure

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Editor's pick
Sangamo Biosciences press release
14 December 2015
New & experimental HIV treatments

The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

Editor's pick
Medicines Patent Pool
3 December 2015
Access to healthcare

Three new agreements announced with the potential to expand access to innovative HIV treatment in low- and middle-income countries

Editor's pick
UNITAID
1 December 2015
New & experimental HIV treatments

Cipla ready to launch low dose HIV drug efavirenz

Editor's pick
Economic Times
1 December 2015